Advancement in high dose therapy and autologous stem cell rescue in lymphoma

doi:10.4252/wjsc.v7.i7.1039

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 7, Issue 7

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (4792)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Tables (1-2) series.

Item

Count

PDF

405

WORD

287

HTML

2086

Tables (1-2)

217

Sum=2995

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

704

Download

1093

Sum=1797

Aug 26, 2015 (publication date) through Nov 19, 2024

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Stem Cells

ISSN

1948-0210

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Minireviews

World J Stem Cells. Aug 26, 2015; 7(7): 1039-1046
Published online Aug 26, 2015. doi: 10.4252/wjsc.v7.i7.1039

Table 1 High dose therapy followed by autologous stem cell transplantation in Hodgkin lymphoma

Ref.	Year	Patients (n)	Status of HL	Regimen	TRM (%)	PFS (%)	OS (%)	Follow-up (mo)
Ramzi et al[5]	2012	45	R/R	CEAM	2.2	77	84	24
Czyz et al[6]	2013	132	R/R	Modified BEAM	-	66	76	68
Shafey et al[7]	2012	73	R/R	DICEP	1	61	80	56
Sinha et al[9]	2013	30	R/R	VTEPA	0	67	81	32
Di Ianni et al[10]	2012	58	R/R	TECA	0	72	82	60

HL: Hodgkin lymphoma; DICEP: Dose-intensive cyclophosphamide, etoposide, cisplatin; VTEPA: Vinorelbine, paclitaxel, etoposide and cisplatin; TECA: Thiotepa, etoposide and carboplatin; R/R: Relapsed/refractory; OS: Overall survival; PFS: Progression free survival.

Citation: Isidori A, Clissa C, Loscocco F, Guiducci B, Barulli S, Malerba L, Gabucci E, Visani G. Advancement in high dose therapy and autologous stem cell rescue in lymphoma. World J Stem Cells 2015; 7(7): 1039-1046
URL: https://www.wjgnet.com/1948-0210/full/v7/i7/1039.htm
DOI: https://dx.doi.org/10.4252/wjsc.v7.i7.1039